

Oncology Markets for Isocitrate Dehydrogenase Inhibitors

Technologies, Therapeutics,
Markets, Strategies &
Opportunities

Report Brochure




Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Oncology Markets for Isocitrate Dehydrogenase Inhibitors** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutics drugs that can inhibit the gain -of-function action of IDH1 or IDH2 and restore cell maturation in tumor cells. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Biomarker-based Oncology Therapeutics

Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment. Recently approved oncology drugs target discrete molecular aberrations or pathways in tumor cells and consequently are active on a subset of patient population, yet clinical studies have shown that not all biomarker-positive patients respond. The advancement of predictive biomarkers needs to detect novel and evolving drug resistance mechanisms, not only to guide the selection of patient subsets for specific treatments, but to identify new therapeutic targets.



- The Opportunity
- Mutated IDH
- Mutated IDH - Mechanisms of Action
- IDH Inhibitor Therapeutics
- Inhibition of IDH
- FDA-Approved IDH Inhibitors
- Development-stage Drugs
- Competing Therapies
- INDICATIONS
- Acute Myeloid Leukemia
- Competing Drugs Prescribed for Treating AML
- FLT3 inhibitors
- Gemtuzumab ozogamicin (Mylotarg)
- Venetoclax (Venclexta)
- Hedgehog pathway inhibitor
- Cholangiocarcinoma
- Glioma
- IDH TESTING
- Non-small Cell Lung Cancer
- Market Factors
- Standards Organizations
- Pharmaceutical Insurance Coverage & Managed Care
- Company Profiles
- AGIOS
- Aslan Pharmaceuticals
- Bayer
- Beigene
- Bristol-Myers Squibb
- Celgene
- Daiichi Sankyo
- Philogen S.p.A.
- Tesaro
- Tragara/Adastr
- Tocagen

What You Will Learn

- Who are the developers and suppliers of IDH inhibitors? What are their capabilities and market strategies?
- What is the competitive landscape for late-stage development IDH inhibitors and what indications are they targeting?
- What is the size of the market for IDH inhibitors today, who are the market share leaders, and what will the market be in 2022?
- How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
- What are the significant economic, technology, and regulatory factors affecting the market for biomarker-based oncology therapeutics?

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-595-4340, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Oncology Markets for Isocitrate Dehydrogenase Inhibitors

Technologies, Therapeutics, Markets, Strategies and Opportunities

Select	Format	License	Price (U.S. Funds)	Total
<input type="checkbox"/>	PDF	Single User License	\$2,850.00	
<input type="checkbox"/>	PDF	Site License	\$4,500.00	
<input type="checkbox"/>	PDF	Global License	\$6,500.00	
Total Payment (U.S. funds)				

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: